source
- Lundbeck advances PACAP-targeting migraine drug after mid-stage trial shows reduction in migraine daysLundbeck reported new data from a mid-stage study of its experimental migraine prevention therapy, bocunebart, which targets the PACAP protein involved in headache pathways. The trial enrolled hun…
- Supreme Court rules generic Vascepa copy does not infringe patents, boosting skinny-label pathwayThe U.S. Supreme Court issued a decision that Hikma Pharmaceuticals’ generic version of Amarin’s heart drug Vascepa does not infringe the brand’s patents. The ruling clarified that the generic make…